Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 5/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 17/20 | 0.60 |
| ▸ | ATF1 | P18846 | 12/20 | 0.60 |
| ▸ | JUN | P05412 | 6/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 6/20 | 0.57 |
| ▸ | RELA | Q04206 | 6/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79014 | 0.86 | NFKB1 (0.60) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL8518174 | 0.84 | NFKB1 (0.62) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL9564861 | 0.84 | NFKB1 (0.58) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL17315283 | 0.84 | NFKB1 (0.58) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL9564875 | 0.83 | NFKB1 (0.57) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL8396850 | 0.81 | XPO1 (0.65) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL6061624 | 0.81 | XPO1 (0.46) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL473934 | 0.80 | ATF1 (0.62) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL15290081 | 0.80 | NFKB1 (0.56) | XPO1NFKB1ATF1JUNNFKB2 | |
| SCHEMBL9564859 | 0.80 | XPO1 (0.46) | XPO1NFKB1ATF1JUNNFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5852190-A | Diazepinoindoles as phosphodiesterase IV inhibitors | INSTITUT DE RECHERCHE JOUVEINAL SA (FR) | 1998-12-22 | — | — | US | claimed |
| US-11672251-B2 | Herbicidally active pyridyl-/pyrimidyl-pyrimidine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2023-06-13 | — | — | US | disclosed |
| US-11672251-B2 | Herbicidally active pyridyl-/pyrimidyl-pyrimidine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2023-06-13 | — | — | US | disclosed |
| US-11672251-B2 | Herbicidally active pyridyl-/pyrimidyl-pyrimidine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2023-06-13 | — | — | US | disclosed |
| EP-3684182-B1 | HERBICIDALLY ACTIVE PYRIDYL-/PYRIMIDYL-PYRIMIDINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2023-06-07 | — | — | EP | disclosed |
| EP-3684182-B1 | HERBICIDALLY ACTIVE PYRIDYL-/PYRIMIDYL-PYRIMIDINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2023-06-07 | — | — | EP | disclosed |
| CN-111372455-B | Herbicidally active pyridyl-/pyrimidinyl-pyrimidine derivatives | 先正达参股股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-3684763-B1 | PYRIMIDIN-4-CARBAMATE OR UREA DERIVATIVES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-11-17 | — | — | EP | disclosed |
| EP-3684763-B1 | PYRIMIDIN-4-CARBAMATE OR UREA DERIVATIVES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-11-17 | — | — | EP | disclosed |
| US-20200288711-A1 | Pyrimidin-4-Carbamate or Urea Derivatives As Herbicides | SYNGENTA PARTICIPATIONS AG (CH) | 2020-09-17 | — | — | US | disclosed |
| WO-2003039549-A2 | SELECTIVE ANTIBACTERIAL AGENTS | 4SC AG (DE) | 2003-05-15 | — | — | WO | disclosed |
| US-20030040513-A1 | P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | US | disclosed |
| EP-1242396-A1 | NEW P2X 7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| EP-0785789-B1 | DIAZEPINO-INDOLES AS PHOSPHODIESTERASE IV INHIBITORS | PFIZER (FR) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001044213-A1 | NEW P2X7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | ASTRAZENECA AB (SE) | 2001-06-21 | — | — | WO | disclosed |
| US-5811428-A | ADMINISTERING FOR THE TREATMENT AND PREVENTION OF IMMUNOINFLAMMATORY AND AUTOIMMUNE DISEASES | SIGNAL PHARMACEUTICALS, INC. (US) | 1998-09-22 | — | — | US | disclosed |
| EP-0850228-A1 | PYRIMIDINE CARBOXAMIDES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1998-07-01 | — | — | EP | disclosed |
| EP-0785789-A1 | DIAZEPINO-INDOLES AS PHOSPHODIESTERASE IV INHIBITORS | INSTITUT DE RECHERCHE JOUVEINAL (I.R.J) (FR) | 1997-07-30 | — | — | EP | disclosed |
| WO-1997009315-A1 | PYRIMIDINE CARBOXAMIDES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
| WO-1996011690-A1 | DIAZEPINO-INDOLES AS PHOSPHODIESTERASE IV INHIBITORS | INSTITUT DE RECHERCHE JOUVEINAL (FR) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040513-A1 | P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases | P2RX1, P2RX2, P2RX3 | XPO1 1312/4885NFKB1 383/4885ATF1 634/4885 |
| US-20200288711-A1 | Pyrimidin-4-Carbamate or Urea Derivatives As Herbicides | PLPBP, DDT, UMPS | XPO1 4599/4885NFKB1 3902/4885ATF1 3200/4885 |
| US-11672251-B2 | Herbicidally active pyridyl-/pyrimidyl-pyrimidine derivatives | PLPBP, PDXK, DPYD | XPO1 4685/4885NFKB1 3880/4885ATF1 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.